Management of epilepsy in Lebanon: Medication reviews and drug-related problems.
adverse drug reactions
drug-drug interactions
drug-related problems
epilepsy
medication review
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
27
12
2021
received:
11
08
2021
accepted:
20
01
2022
pubmed:
28
1
2022
medline:
9
4
2022
entrez:
27
1
2022
Statut:
ppublish
Résumé
The goal of epilepsy treatment is to control seizures without drug related problems (DRPs). The evaluation of anti-seizure drugs (ASD) strategies and identification of DRPs are rarely studied. This study aimed primarily to evaluate the choice of ASD according to international guidelines and secondarily to identify and describe anti-seizure drug-related problems. A cross-sectional study was conducted during 1 year among Lebanese adults with epilepsy attending neurology clinics. The choice of ASD was compared to National Institute for Health and Care Excellence guidelines. Drug-drug interactions were evaluated by the Lexicomp database, and the DRP classification was performed using the Pharmaceutical Care Network Europe classification. A total of 404 patients with epilepsy were included. The prescription for an ASD was in accordance with the indication set in guidelines in 75.0% of population, and 1078 DRPs were identified. The main DRPs detected were adverse drug reactions (51.0%), inappropriate combinations of drugs (50.0%), and suboptimal drug regimens (46.3%). Single and divorced patients, who living in Mount Lebanon, and who took the old with the new generation had a less risk to have an inadequate prescription to guidelines. However, female gender, controlled epilepsy, multiple ASDs, and living in a rural region increased DRPs. This study showed that quarter of the population used ASDs contraindicated according to international guidelines. Since DRPs were related to the number and type of ASD prescribed, it is important to assess the case of each patient by a clinical pharmacist to prevent drug-drug interactions and iatrogenic issues.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-591Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Ngugi A, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883-890.
Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49:1491-1503.
Kerr M, Guidelines Working Group, Scheepers M, et al. Consensus guidelines into the management of epilepsy in adults with an intellectual disability. J Intellect Disabil Res. 2009;53:687-694.
Mehta DC, Short JL, Hilmer SN, Nicolazzo JA. Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights. Pharm Res. 2015;32:819-839.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-255.
Manan MM, Rusli RA, Ang WC, Al-Worafi YMA, Ming LC. Assessing the pharmaceutical care issues of antiepileptic drug therapy in hospitalised epileptic patients. J Pharm Pract Res. 2014;44:83-88.
Foppe van Mil JW, Westerlund T, Brown L, et al. Medical care and drug-related problems: do doctors and pharmacists speak the same language? Int J Clin Pharm. 2016;38:191-194.
PCNE. PCNE DRP classification 8.02 - Pharmaceutical Care Network Europe, 2018. https://www.pcne.org/news/68/pcne-drp-classification-now-802. Accessed August 22, 2019.
Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31:199-205.
Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155:1949-1956.
Koshy S. Role of pharmacists in the management of patients with epilepsy. Int J Pharm Pract. 2012;20:65-68.
George J. Evaluation of drug utilization and analysis of anti- epileptic drugs at tertiary care teaching hospital. IJOPP. 2016;9:189-194.
Rishe W, Seifu MF, Gelaw BK, Gunasekaran T, Tadesse E, Gebremariam MA. Drug use evaluation of antiepileptic drugs in outpatient epilepsy clinic of Bishoft general hospital, East Shoa, Ethiopia. Indo Am J Pharm Res. 2015;5:951-962.
Mroueh L, Boumediene F, Jost J, et al. Self-reported attitudes about medication in Lebanese people with epilepsy. Epilepsy Behav. 2019;98:80-87.
Al-Hajje A, Atoui F, Awada S, Rachidi S, Zein S, Salameh P. Drug-related problems identified by clinical pharmacist's students and pharmacist's interventions. Ann Pharm Fr. 2012;70(3):169-176.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35:121-126.
Bedru B. Assessment of drug therapy problems among ambulatory epileptic patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia, 2018. http://etd.aau.edu.et/handle/123456789/13510. Accessed December 2, 2021.
Nasir BB, Berha AB, Gebrewold MA, Yifru YM, Engidawork E, Woldu MA. Drug therapy problems and treatment satisfaction among ambulatory patients with epilepsy in a specialized hospital in Ethiopia. PLoS One. 2020;15(1):1-12.
WHO. WHO | Process of translation and adaptation of instruments. WHO 2007. http://www.who.int/substance_abuse/research_tools/translation/en/. Accessed May 27, 2019.
Preux PM. Questionnaire in a study of epilepsy in tropical countries. Bull Soc Pathol Exot. 2000;93:276-278.
LICE. Guidelines for epidemiologic studies on epilepsy. Commission on epidemiology and prognosis, international league against epilepsy. Epilepsia. 1993;34:592-596.
Smithson WH, Hukins D, Buelow JM, Allgar V, Dickson J. Adherence to medicines and self-management of epilepsy: a community-based study. Epilepsy Behav. 2013;26:109-113.
Ferrari CMM, de Sousa RMC, Castro LHM. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013;22:384-389.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-521.
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522-530.
Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74:573-580.
Bulajeva A, Labberton L, Leikola S, et al. Medication review practices in European countries. Res Social Adm Pharm. 2014;10:731-740.
Jokanovic N, Tan ECK, van den Bosch D, Kirkpatrick CM, Dooley MJ, Bell JS. Clinical medication review in Australia: a systematic review. Res Social Adm Pharm. 2016;12:384-418.
Leikola S, Tuomainen L, Peura S, et al. Comprehensive medication review: development of a collaborative procedure. Int J Clin Pharmacol. 2012;34:510-514.
Leikola SNS, Virolainen J, Tuomainen L, Tuominen RK, Airaksinen MSA. Comprehensive medication reviews for elderly patients: findings and recommendations to physicians. J Am Pharm Assoc. 2003;2012(52):630-633.
Wang PS, Demler O, Kessler RC. Adequacy of treatment for serious mental illness in the United States. Am J Public Health. 2002;92:92-98.
NICE. Overview | Epilepsies: diagnosis and management | Guidance | NICE, 2018. https://www.nice.org.uk/guidance/cg137. Accessed August 22, 2019.
Lexicomp Online. http://webstore.lexi.com/ONLINE. Accessed July 27, 2019.
Liu P, Li G, Han M, Zhang C. Identification and solution of drug-related problems in the neurology unit of a tertiary hospital in China. BMC Pharmacol Toxicol. 2021;22:65.
Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. J Pharm Health Serv. 2013;4:155-158.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6-14.
Wassenaar M, Van IH, Leijten FS, et al. Treatment of epilepsy in daily clinical practice: have outcomes improved over the past 10 years? J Neurol. 2013;260:2736-2743.
Bosak M, Słowik A, Iwańska A, Lipińska M, Turaj W. Co-medication and potential drug interactions among patients with epilepsy. Seizure-Eur J Epilep. 2019;66:47-52.
Gosch M, Wörtz M, Nicholas JA, Doshi HK, Kammerlander C, Lechleitner M. Inappropriate prescribing as a predictor for long-term mortality after hip fracture. J Gerontol. 2014;60:114-122.
Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H. Drug-related hospital admissions among old people with dementia. Eur J Clin Pharmacol. 2016;72:1143-1153.
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-140.
Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017;18(1):52-62.
Tang F, Zhu G, Jiao Z, Ma C, Wang B. Self-reported adherence in patients with epilepsy who missed their medications and reasons for nonadherence in China. Epilepsy Behav. 2013;27:85-89.
Karakurt P, Kaşikçi M. Factors affecting medication adherence in patients with hypertension. J Vasc Nurs. 2012;30:118-126.
Martin MY, Kohler C, Kim Y, et al. Taking less than prescribed: medication nonadherence and provider-patient relationships in lower-income, rural minority adults with hypertension. J Clin Hypertens (Greenwich). 2010;12:706-713.